Skip to main content

Adjuvant Non Small Lung Cancer TroFuse-019

Status: Open to Enrollment
Email us to enroll

Study details

View study details on www.clinicaltrials.gov.

Locations

  • San Francisco

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Alan M Kramer, M.D.
Alan M Kramer, M.D.
Principal investigator
View profile

Sub-Investigator

Kevin B Kim, M.D.

Email us to enroll

Related clinical trials

View all clinical trials
  • Clinical trial

    Adjuvant Early-stage Non-small Cell Lung Cancer Beamion LUNG-3

    Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Monotherapy vs. Standard of Care Early-stage, Resectable Non-small Cell Lung Cancer

    Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

    Status: Coming Soon

  • Clinical trial

    Adjuvant Non-Small Cell Lung Cancer A081801

    Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Non-Small-Cell Lung Cancer C5851005 PADL1NK-005

    PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

    Status: Open to Enrollment

  • Clinical trial

    Advanced Non-Small Cell Lung Cancer S1900K

    A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?